Journal: Molecular Pharmacology
Article Title: Elucidating the binding and metabolic interactions of sunitinib and sorafenib with Cytochrome P450s CYP2U1 and CYP2D6
doi: 10.1016/j.molpha.2026.100114
Figure Lengend Snippet: Tyrosine kinase inhibition by sunitinib, sorafenib, and their CYP-derived metabolites. (A) Experimental scheme of a sandwich ELISA to determine levels of phosphorylation in cell extracts. (B) Absorbances at 450 nm were taken to estimate degree of phosphorylation by tyrosine kinases naturally expressed in HEK293 cells when different concentrations of tumor-targeting drugs and their CYP-derived metabolites were dosed. Dimethyl sulfoxide was used as vehicle control. One-way ANOVA followed by Tukey’s post hoc test was done to deduce significance between cells only control and all dosage groups. ∗ P < .05, ∗∗ P < .01, ∗∗∗ P < .001. The experiment was done in 3 to 5 replicates with errors indicated. TMBZ, 3,3′,5,5′-tetramethylbenzidine.
Article Snippet: Total tyrosine kinase activity was quantified using a sandwich ELISA kit (Universal Tyrosine Kinase Assay Kit, Takara Biosciences).
Techniques: Inhibition, Derivative Assay, Sandwich ELISA, Phospho-proteomics, Control